Dr. Bass’ recent article in Contemporary Pediatrics, “Personalized medicine, right drug, right patient, right time,” provides a miniature but profound view of what may be the future of pediatric healthcare: focusing on healthcare that is truly individualized through precision science in the areas of diagnosis and treatment, rather than generalized, population-based treatment guidelines.
The premise is to use a patient’s own genetic information to guide decisions for prevention, diagnosis, and treatment of disease and other health conditions.
Diagnosis of attention-deficit/hyperactivity disorder (ADHD) at age 9 years is associated with adverse childhood experiences (ACEs), according to an analysis of data for 1572 children who are part of the Fragile Families and Child Wellbeing Study (FFCWS) birth cohort.
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a controversial UK-based study published in JAMA Pediatrics that examined how well pharmacologic interventions for attention-deficit/hyperactivity disorder (ADHD) help education and health outcomes for impacted kids.
A longitudinal study examined the relationship between prenatal or postnatal high-fat, high-sugar diet and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children who demonstrated either early-onset persistent conduct disorder or minimal conduct problems.
New research examines the effects of behavioral, psychostimulant, and combined treatments on homework issues among children with attention-deficit/hyperactivity disorder (ADHD).
Treating allergic rhinitis (AR) in children with attention-deficit/hyperactivity disorder (ADHD) appears to significantly improve not only AR, but also ADHD symptoms.
Despite concerns about ADHD stimulant therapy as a gateway for future drug abuse, a new study shows that teens treated with stimulants later and for shorter durations, and those treated with non-stimulant medications, have higher rates of later drug abuse than their peers who have used stimulant therapy longer.
The amount of off-label uses of atypical antipsychotic drugs (AAPs) prescribed for children with attention-deficit/hyperactivity disorder (ADHD) raises questions about the appropriateness of AAPs for this indication.
For Contemporary Pediatrics, Dr Bobby Lazzara explains key findings from a study published in the Journal of Attention Disorders. The study looked at whether there was a correlation between ADHD and frustration tolerance in children.